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Abstract
In chronic HCV infection, treatment failure and defective host immune response highly demand improved therapy
strategies. Vc9Vd2 T-cells may inhibit HCV replication in vitro through IFN-c release after Phosphoantigen (PhAg)
stimulation. The aim of our work was to analyze Vc9Vd2 T-cell functionality during chronic HCV infection, studying the role
of IFN-a on their function capability. IFN-c production by Vc9Vd2 T-cells was analyzed in vitro in 24 HCV-infected patients
and 35 healthy donors (HD) after PhAg stimulation with or without IFN-a. The effect of in vivo PhAg/IFN-a administration on
plasma IFN-c levels was analyzed in M. fascicularis monkeys. A quantitative analysis of IFN-c mRNA level and stability in
Vc9Vd2 T-cells was also evaluated. During chronic HCV infection, Vc9Vd2 T-cells showed an effector/activated phenotype
and were significantly impaired in IFN-c production. Interestingly, IFN-a was able to improve their IFN-c response to PhAg
both in vitro in HD and HCV-infected patients, and in vivo in Macaca fascicularis primates. Finally, IFN-a increased IFN-c-
mRNA transcription and stability in PhAg-activated Vc9Vd2 T-cells. Altogether our results show a functional impairment of
Vc9Vd2 T-cells during chronic HCV infection that can be partially restored by using IFN-a. A study aimed to evaluate the
antiviral impact of PhAg/IFN-a combination may provide new insight in designing possible combined strategies to improve
HCV infection treatment outcome.
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Introduction
Most Hepatitis C virus (HCV) infections evolve in persistent
infection, which may progress to fibrosis, cirrhosis, liver failure or
even hepatocellular carcinoma [1]. Current standard therapy is
based on a combination of pegylated (PEG)-IFN-a and ribavirin
(RBV) and treatment response may be influenced by several virus-
related factors such as HCV genotype and baseline titer of HCV
RNA [2,3]. A sustained virological response (SVR) occurs in
approximately 80% of patients infected with HCVgenotypes 2 or3,
and in approximately 45% for genotypes 1 or 4 [4]. New antiviral
strategies are currently in development for HCV infection and
include drugs targeting key viral enzymes such as NS3-4A and the
NS5B RNA-dependent RNA polymerase [5]. Although effective,
the use of these new antivirals seems associated to the selection of
drug-resistant HCV variants, resulting in viral breakthrough. Thus,
a combination between antivirals and standard treatment with IFN-
a and RBV is therefore necessary [3,6].
HCVpersistenceis mainlydueto the failure ofthe host’s immune
system to effectively and definitively clear the infection and generate
protective cellular immunity. Indeed, marked quantitative and
qualitative defects of HCV-specific CD8 T-cells have been
described in HCV patients, correlated with innate immune cell
impairment such as dendritic cell (DC) [7] and NK cells [8–10]. In
this context, immune modulation could represent a promising
strategy aimed to restore protective immune response, inducing a
long lasting immunity, necessary to obtain viral eradication.
Among innate immune cells, Vc9Vd2 T-cells represent a good
target for immunotherapy in infectious diseases [11,12] for their
multifaceted response capability [13]. They may specifically be
activated both in vitro and in vivo by using phosphoantigens (PhAgs)
[14] and aminobisphosphonates [15] without any MHC restric-
tion. They elicit a dual antimicrobial activity, by directly affecting
microbial replication [13,16] and by modulating other cell subsets
such as DC activation and maturation [17], neutrophils recruit-
ment and activation [18], and Th1 immune response polarization
[19].
Vc9Vd2 T-cells are involved in host response to many chronic
viral infections, including HCV [13]. As observed in other chronic
infection such as HIV [20], a decrease of peripheral Vc9Vd2T -
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Activated Vc9Vd2 T lymphocytes were found able to inhibit
subgenomic HCV replication, and this effect was mediated mainly
by IFN-c release [21]. A role of recombinant IFN-c on sub-
genomic HCV replication was also described [22]. Moreover,
several studies showed that the combination of recombinant IFN-c
and IFN-a resulted in a strongly enhanced antiviral activity in the
HCV replicon model, opening the way to new combined treat-
ment approaches. Thus, IFN-c induced by Vc9Vd2 T-cell sti-
mulation could enhance standard treatment effectiveness.
In this work, phenotype and function of Vc9Vd2 T-cells were
analyzed during chronic HCV infection, evaluating possible strat-
egies aimed to improve their effector response. This approach was
validated in vivo in a non-human primate model.
Methods
Ethics statement
This study was approved by the Ethics Committee of the
National Institute for Infectious Diseases ‘‘L.Spallanzani’’, and all
enrolled individuals provided written informed consent.
All experiments on monkeys were performed in accordance with
the recommendations of the Weatherall report, and were previ-
ously approved by the regional ethical committee (Comite ´R e ´gional
d’Ethique en Matie `re d’Expe ´rimentation Animale de Strasbourg:
C.R.E.M.E.A.S.) (number approval: AL/01/01/01/06).
Patients
24 HCV-infected patients (16 males and 8 females, mean age:
54.9610.7) naı ¨ve to treatment, and 35 healthy age-matched indi-
viduals (HD, 25 males and 10 females, mean age: 50.3613.2),
were recruited at the INMI L. Spallanzani. Patients clinical fea-
tures are described in Table 1. This study was approved by the
Ethics Committee of the Institute, and all enrolled individuals
provided written informed consent.
Plasma HCV quantification and genotyping
Plasma HCV-RNA levels were assayed by Abbott RealTi-
meHCV assay (Abbott Laboratories. Abbott Park, Illinois, U.S.A.).
Moreover, HCV genotype was determined by Abbott RealTime
HCV Genotype II Amplification Reagent kit.
Lymphocytes isolation and cd T cell purification
Peripheral blood mononuclear cells (PBMC) were isolated by
Lympholyte (Cedarlane, Canada). In selected experiments, cd T-
cells were purified from PBMC by immunomagnetic separation
using anti-cd-conjugated magnetic microbeads (Miltenyi Biotec,
Germany). The purity of cells fraction was .95% in all experi-
ments, as measured by flow cytometry analysis (data not shown).
Vc9Vd2 T-cell phenotyping
Phenotypic analysis of Vd2 T-cells from HCV and from HD was
performed by flow cytometry. Specifically, Vd2 T-cell subsets were
analyzed by using the following monoclonal antibodies: anti- Vd2
FITC (clone IMMU389), anti-CD3 PerCP-PC5 (clone UCHT-1),
from Beckman Coulter (Immunotech, France); anti-CD27 APC
(clone L128), anti-CD45RA CY-Chrome (clone HI100), anti-CD69
APC-Cy7 (clone FN50), anti-CD25 APC (clone M-A251) from BD
Biosciences (San Jose, CA, USA). Briefly, thawed PBMC (1610
6
cells/ml) were incubated with mAbs cocktail for 15 min a 4uC,
washed twice with wash buffer (PBS 16, 0.1% NaN3, 1% BSA) and
fixed with 1% paraformaldehyde (PFA, Sigma, St. Louis, MS).
Samples acquisition and data analysis were performed by a FACS
Canto II flow cytometer (Becton Dickinson) by using Diva software.
Cytokines production
Cytokine production by Vc9Vd2 T-cells was tested by using a
synthetic PhAg (IPH1101, Innate-Pharma, France) able to specif-
ically activate only Vc9Vd2 T-cells [14]. Specifically, purified
Vc9Vd2 T-cells from HD (n=6) and PBMC from HD (n=35) or
HCV-patients (n=24) were stimulated with single PhAg (IPH1101:
3 mM), single IFN-a-2b (100 IU/ml, Schering-Plough, Belgium) or
PhAg plus IFN-a-2b combined stimulation; IFN-c production was
evaluated after 18 hours by ELISA test (Thermo Scientific, USA).
Moreover, in selected HCV and HD, the frequency of IFN-c-
producing Vc9Vd2 T-cells was monitored. Briefly, PBMC were
stimulated for 18 h with PhAg or PhAg/IFN-a in the presence
of Brefeldin A (10 mg/ml) (Serva, Germany) to block cytokine
secretion. Intracellular staining was performed by staining cells for
15 minutes at 4uC with anti-Vd2 FITC antibody; after washing,
cells were fixed with 1% PFA (Sigma, St. Louis, MS) and stained at
room temperature with an APC-labeled IFN-c specific antibody
(clone B27), in permeabilizing solution (PBS 16, 0.1% NaN3, 1%
BSA, 0.5% saponin). After washing (PBS 16, 0.1% NaN3, 1%
BSA, 0.1% saponin), cells were acquired by flow cytometer (FACS
Canto II flow cytometer) and data were analyzed by using Diva
software. The frequency of IFN-c-producing Vc9Vd2 T-cells and
the IFN-c MFI (Median Fluorescence Intensity) were compared
between HD and HCV-infected patients.
In vivo drug administration and cytokine quantification
in animal system
8n a ı ¨ve cynomologus macaques (Macaca fascicularis) were included
in the study: 6 animals were purchased from Noveprim (Ferney S.E,
Mahebourg, Mauritius) and 2 from CDP(ULP Strasbourg, France).
Animal welfare conditions conformed to the European require-
ments, comprising monitored temperature, humidity, air change,
and lighting cycle. All experiments were previously approved by the
regional ethical committee (Comite ´R e ´gional d’Ethique en Matie `re
d’Expe ´rimentation Animale de Strasbourg: C.R.E.M.E.A.S.) (num-
ber approval: AL/01/01/01/06). At the beginning of the study,
body weights ranged from 2.2 to 5.8 kg. In order to avoid suffering,
animals were anaesthetized with Ketamine 1000 ND (10 mg/kg
IM)beforeanyprocedure.Group1(4animals)wasinjecteds.c.with
3 mg/Kg of IPH1201 (C-HDMAPP) a second generation synthetic
PhAg able to specifically activate Vc9Vd2 T-cells (Innate-Pharma,
France) (solution 4%, borate buffer). Group 2 (4 animals) was
injected subcutaneously (s.c.) with 3 mg/Kg of IPH1201 and with
27 mg/animal s.c. of Interferon a-2a pegylated, PegasysH (Roche).
Table 1. Main clinical features of Healthy Donors (HDs) and
HCV patients.
Group Gender Age AST ALT HCV HCV
(M/F) (years) (mU/ml) (mU/ml) Genotype VL (log)
HD 25/10 50.3613.2 22.868.2 21.667.1 n.t. n.t.
(n=35)
HCV 16/8 54.9610.7 60.7634.4 55.0639.6 1 (n=11) 5.9560.59
(n=24) 2 (n=5)
3( n=5 )
4( n=3 )
n.t.: not tested.
doi:10.1371/journal.pone.0037014.t001
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HCV patients. Blood samples were collected before and after 4, 8,
12, 16, 20, 24, 28 hours after treatment, and sera were stored for
further analysis. IFN-c plasma levels were analyzed by ELISA
(Biosource).
Analysis of IFN-c-mRNA level and stability
RNA from purified cd T cells was extracted with Trizol reagent
(Invitrogen, USA). One mg total RNA was reverse transcribed by
TaqMan Reverse Transcription Reagent kit (Applied Biosystems,
USA) according to manufacturer’s instructions. IFN-c-mRNA
level was quantified by qPCR performed using Taqman 26PCR
Master mix (Applied Biosystems, USA) and a 7900 HT Fast Real-
Time PCR system machine by using primers and probe sets for
IFN-c-mRNA and b-actin as described in [23]. Results are ex-
pressed as normalized to b-actin expression.
mRNA stability was evaluated by adding 10 mg/ml actinomycin
D (ActD) after 18 hours of PhAg (IPH1101: 3 mM) or IFN-a
(100 IU/ml) stimulation. IFN-c-mRNA levels were evaluated by
qRT-PCR just before Actinomycin addiction (t0), and after 30 and
120 minutes of culture, and expressed as normalized to b-actin.
mRNA stability was evaluated by calculating half-life times of
IFN-c-mRNA by linear regression (GraphPad Prism).
Statistical analysis
Statistical significance was determined by GraphPad Prism
software (GraphPad). Differences between groups were evaluated
by non parametric Mann-Whitney test; Wilcoxon test was used
when comparing different culture conditions of the same cells.
Tests were considered significant when p,0.05. IFN-c-mRNA
half life was evaluated by linear regression.
Results
Vc9Vd2 T-cell phenotype and function in HCV-infected
patients
Vc9Vd2 T-cell subsets were analyzed in 24 HCV-infected
patients (HCV), naı ¨ve to treatment, and compared with 35 healthy
donors (HD). In chronic HCV patients a slight but significant
decrease in circulating Vc9Vd2 T-cell frequency was observed
[HCV: median 1.140% (IQR: 0.49–2.16) vs. HD: 1.770% (1.080–
2.290), p=0.0362, Figure 1A], confirming previous results [10].
Moreover, Vc9Vd2 T-cell differentiation profile showed a signi-
ficant increase in Vc9Vd2 effector cells (CD45RA+CD27-) in
HCV patients [HCV: median 6.5 (IQR: 3.5–13.0) vs. HD: 2.2
(0.7–7.2), p=0.0214], suggesting that chronic HCV infection
induced Vc9Vd2 T-cell differentiation toward effector functions
(Figure 1A–B). Moreover, CD25 and CD69 expression on Vc9Vd2
T-cells were slightly but significantly increased in HCV patients as
compared to HD [CD25: HCV median 0.8% (IQR 0.2–2.0) vs.
HD 0.0% (IQR: 0–0.6), p=0.0435; CD69: HCV median 1.6 (IQR
0.9–4.8) vs. HD 0.7 (IQR: 0.6–0.9), p=0.0317, Figure 1C–D],
suggesting that HCV-induced chronic inflammation may increase
basal activation of these cells.
It is well known that PhAgs specifically activate only Vc9Vd2T -
cell subset inducing IFN-c release [14]. Thus, IFN-c production
by Vc9Vd2 T-cells from HCV-infected patients (n=24) and HD
(n=20) was analyzed by stimulating PBMC for 18 hours with
aV c9Vd2 T-cells specific PhAg (3 mM). The amount of IFN-c
released in supernatants was measured by ELISA (Figure 2A).
PBMC from HCV patients showed a profound impairment in
IFN-c production after PhAg stimulation [HCV: median 4.4 pg/
ml (IQR: 0.0–14.9) vs. HD: 77.1 pg/ml (69.5–158.1), p,0.0001].
Finally, we wondered whether the lower IFN-c production
observed in chronic HCV infected patients was the result of a
decreased frequency of IFN-c-producing Vc9Vd2 T-cells, or of a
reduced amount of IFN-c produced by each cell. To this aim, we
quantified the frequency of IFN-c-producing Vc9Vd2 T-cells by
intracellular staining and flow cytometry. As shown in Figure 2B,
no statistically significant differences in the frequency of PhAg-
stimulated Vc9Vd2 T-cells between HD and HCV was observed,
suggesting that HCV infection reduced the amount of IFN-c
produced by each responding cells. Indeed, the IFN-c MFI after
PhAg stimulation was lower in HCV patients than in healthy
donors [HCV-MFI: 13830 (IQR: 12240–18440) vs. HD-MFI:
40340 (IQR: 38652–51900), p,0.05, Figure 2C], confirming a
reduced capability of each responding cells to produce IFN-c.
Moreover, a slight percentage of Vc9Vd2 T-cells from HCV-
infected patients were able to produce IFN-c in the absence of
antigenic stimulation [HCV: median 0.9% (IQR: 0.35–1.75) vs.
HD: 0% (0–0.34), p,0.05], Figure 2b), confirming an activated/
effector phenotype.
IFN-a improves in vitro and in vivo Vc9Vd2 T-cell
responsiveness to PhAg stimulation in HD and in non-
human primates
In order to evaluate whether IFN-a could improve Vc9Vd2T -
cell responsiveness to PhAg, purified Vc9Vd2 T-cells were sti-
mulated with single PhAg (3 mM), single IFN-a (100 IU/ml) and
combined (PhAg/IFNa) for 18 hours. At the end of incubation
IFN-c released by Vc9Vd2 T-cells was evaluated by ELISA test
(Figure 3A). As shown in Figure 3A, IFN-a was able to improve
IFN-c release by Vc9Vd2 T-cells [PhAg: median 1996 pg/ml
(IQR: 1791–2115) vs. PhAg/IFNa: 2953 (2550–3042), p,0.05].
Moreover, dose response experiments showed that IFN-a did not
modify EC50 of PhAg but it was able to induce a dose dependent
increase of IFN-c production (data not shown).
To verify if IFN-a could also improve in vivo Vc9Vd2 T-cell
responsiveness to PhAg stimulation, non-human primates (M.
Fascicularis) were injected with 3 mg/Kg s.c. of PhAg (Group 1,
n=4) or with 3 mg/Kg of PhAg s.c. and 27 mg/animal s.c. of
PEG-IFN-a (Group 2, n=4). Plasma IFN-c levels were analyzed
before administration, and after 4, 8, 12, 16, 20, 24, 28 hours. As
shown in Figure 3B, no IFN-c was found before treatment, and a
single injection of PhAg resulted in an increase in plasma IFN-c
level, reaching a peak after 4 hours, declining afterwards. Inter-
estingly, the combined injection of IFN-a and PhAg was able to
strongly increase IFN-c release (Cmax PhAg: 1,370 pg/ml vs. Cmax
PhAg/IFN-a: 2,155 pg/ml), showing that PhAg/IFN-a combina-
tion is able to boost in vivo IFN-c production.
IFN-a improves in vitro Vc9Vd2 T-cell responsiveness to
PhAg stimulation in HCV-infected patients
Since IFN-a was able to improve Vc9Vd2 T-cell responsiveness
in HD, we wondered whether it can restore the impaired func-
tional activities of Vc9Vd2 T-cells during chronic HCV infection.
To this aim, IFN-c production (Figure 4) after 24 hours of single
PhAg (3 mM), single IFN-a (100 IU/ml), or combined (PhAg/
IFNa) in vitro stimulations was evaluated on PBMC from 24 HCV-
infected patients and 35 HD. Figure 4 shows that IFN-a was able
to increase IFN-c production by Vc9Vd2 T-cells after PhAg
stimulation both in HD [HD: PhAg: median 77.1 (IQR: 69.5–
158.1) vs. PhAg/IFNa: 147.9 (119.9–221.6), p=0.004, Figure 4A]
and in HCV-infected patients [HCV: PhAg: median 4.4 (IQR:
0.0–14.9) vs. PhAg/IFNa: 21.8 (5.6–47.4), p,0.0001, Figure 4B].
Notably, in HCV-infected patients, IFN-c production by Vc9Vd2
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37014Figure 1. Chronic HCV infection induces an increase in activated/effectors Vc9Vd2 T-cells. (A) Representative flow cytometry panels on
Vc9Vd2 T-cells frequency and differentiation profile are shown for one healthy donor and one HCV-infected patient. Differentiation was analyzed by
monitoring CD27 and CD45RA expression. Naı ¨ve: CD45RA+CD27+; Central Memory: CD45RA-CD27+; Effector Memory: CD45RA-CD27-; Effectors:
CD45RA+CD27-. (B) Statistical analysis of Vc9Vd2 T-cell differentiation profile from HD (white boxes, n=35) and HCV (grey boxes n=24) was
performed by Mann-Whitney test. *p,0.05. (C) Representative flow cytometry panels on CD25 and CD69 expression on Vc9Vd2 T-cells are shown for
one healthy donor and one HCV-infected patient. (D) Statistical analysis of CD25 and CD69 expression on Vc9Vd2 T-cells from HD (white boxes,
n=35) and HCV (grey boxes n=24) was performed by Mann-Whitney test. *p,0.05.
doi:10.1371/journal.pone.0037014.g001
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in HD. Nevertheless, the relative impact of IFN-a in improving
individual Vc9Vd2 T-cell responsiveness was higher in HCV-
infected patients than in HD (Figure 4C).
IFN-a improves and stabilizes PhAg-induced IFN-c –
mRNA
A quantitative analysis of IFN-c-mRNA after PhAg and PhAg/IFN-
a stimulations of purified Vc9Vd2 T-cells was performed by qRT-
PCR (Figure 5A). As expected, PhAg induced a significant increase in
IFN-c-mRNA [IPH1101: 40.8 (IQR: 33.7–48.9) vs. medium: 2.4 (1.5–
21.5), p=0.0286], while IFN-a alone did not induce any IFN-c-
mRNA. Interestingly, the combined stimulation by PhAg and IFN-a
strongly enhanced IFN-c-mRNA expression (PhAg/IFN-a: 84.4
(68.5–110.1) vs PhAg: 40.8 (IQR: 33.7–48.9), p=0.0286), suggesting
that IFN-a increased PhAg-induced IFN-c-t r a n s c r i p t i o n( F i g u r e5 A ) .
IFN-c-mRNA persistence was studied by blocking transcription
with actinomycin D after 18 hours of stimulations (Figure 5B). We
defined 100% IFN-c-mRNA as the amount, normalized to b-
actin mRNA, found after 18 hours of stimulation, just before
actinomycin D addition. IFN-c-mRNA level was measured after
30 and 120 minutes after actinomycin D addition, and mRNA
half-life was calculated by regression analysis. As reported in
Figure 5B, IFN-c-mRNA from non stimulated and IFN-a
stimulated Vc9Vd2 T-cells rapidly decreased after the addiction
of actinomycin D (half-life: 67.4 and 62.3 min. respectively).
Differently, IFN-c-mRNA induced by PhAg stimulation persisted
much longer (half-life: 123 min.), while the combined stimulation
by PhAg and IFN-a highly improved IFN-c-mRNA half life
(367 min.), suggesting that the combined action of PhAg and IFN-
a could be at least partially mediated by an increased stabilization
of IFN-c mRNA.
Figure 2. Chronic HCV infection induces a strong impairment
in IFN-c production. (A) A quantitative analysis of IFN-c produced by
unstimulated and PhAg-stimulated Vc9Vd2 T-cells from HD (n=20,
white boxes) and HCV (n=24, grey boxes) was performed by ELISA
assay. (B) The frequency of IFN-c-producing Vc9Vd2 T-cells after PhAg
stimulation was analyzed by intracellular staining and flow cytometry.
Statistical analysis was performed by Mann-Whitney test, *p,0.05;
***p,0.0001. (C) Representative flow cytometry histograms of IFN-c
MFI (Median Fluorescence Intensity) produced by Vc9Vd2 T-cells after
PhAg stimulation are shown for one healthy donor and one HCV-
infected patient.
doi:10.1371/journal.pone.0037014.g002
Figure 3. IFN-a improves PhAg-induced IFN-c production by
Vc9Vd2 T-cells in HD and in non-human primates. (A)A
quantitative analysis of IFN-c production was performed in vitro by
stimulating purified Vc9Vd2 T-cells from 6 HD by ELISA after medium
(white boxes), IFN-a (grey boxes), PhAg (hatched boxes) and PhAg/IFN-
a (dark grey boxes) stimulation. Statistical analysis was performed by
Mann-Whitney test, **p,0.01 ***p,0.0001. (B) Plasma IFN-c levels
from in vivo PhAg (white dots, n=4) and PhAg/IFN-a (black dots, n=4)
treated monkeys was quantified by ELISA test.
doi:10.1371/journal.pone.0037014.g003
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Main aim of our work was to study the effects of chronic HCV
infection on Vc9Vd2 T-cell phenotype and function, and on pos-
sible strategies aimed to improve their effector activity.
Chronic HCV infection induced a slight but significant decrease
in the frequency of Vc9Vd2 T-cells. An increased liver tissue
compartmentalization of these cells may represent an additional
factor [24]. Differentiation and activation profile analysis of
Vc9Vd2 T-cells showed an increase in circulating effector and
activated cells. These data may be explained in the context of a
chronic infection leading to a persistent stimulation of immune
cells, driving their activation and differentiation. In our patients,
no correlation was found between Vc9Vd2 T-cells dysfunction
and any clinical parameter.
Vc9Vd2 T-cells play a pivotal role in viral infections, for their
ability to mediate broad antiviral and immunomodulating
activities [13,19]. Specifically, antiviral role of activated Vc9Vd2
T-cells, mainly mediated by IFN-c release, has been demonstrated
for several viruses such as coronavirus [25], orthopoxvirus [26],
HIV [27], and HCV [21]. In our work, a severe functional
inability of Vc9Vd2 T-cells to produce IFN-c was shown in HCV
patients, independently from viral load and genotype. Other
innate immune cells are known to show quantitative and qua-
litative defects during chronic HCV infection such as DC [28] and
NK cells [8–10], that could be associated to adaptive immune
response dysfunction and/or exhaustion [28]. In this context, a
complex network of different signals can act to induce immune cell
exhaustion, such as chronic inflammation, persistent antigen
stimulation, and/or direct viral effects [29]. Chronic inflammation
and persistent antigen stimulation, as observed during HIV
infection, may result in Vc9Vd2 T-cell exhaustion and anergy
through activation-induced cell death [30], or through a decrease
in Vc9Vd2 T-cells response by down-modulating CD3-j chain
expression [31]. Finally, although controversial [32,33], a possible
direct HCV-driven inhibition of NK cell function through HCV-
E2/CD81 binding has been reported [34]. Interestingly, CD81
expression by cd T-cells was previously reported [35]. A study
aimed to define cellular and molecular mechanisms involved in
Vc9Vd2 T-cells exhaustion during chronic HCV infection may be
useful to evaluate possible strategies to restore their activity.
The main result of our work is the demonstration that Vc9Vd2
T-cell function may be improved by IFN-a both in HD and in
HCV-infected patients, resulting in a higher IFN-c production. A
first demonstration that type-I IFN may be sensed by Vc9Vd2T -
cells was reported by Kunzmann et al., showing an increase of
CD69 after IFN-a treatment [36]. We confirmed this observation
(data not shown) and showed the ability of IFN-a to increase
Vc9Vd2 T-cell response to PhAgs stimulation in terms of IFN-c
production both in HD and in HCV-infected patients. In par-
ticular, the significant impairment of Vc9Vd2 T-cells in HCV-
infected patients did not allow to obtain their complete restoration
by IFN-a. Nevertheless, individual relative impact of PhAg/IFN-a
co-stimulation was found much higher in HCV patients, due to
the very low level of responsiveness to PhAgs. Thus, the possibility
to restore IFN-c production in vivo by combining standard IFN-a
treatment and PhAg stimulation may have a positive impact on
HCV inhibition. Indeed several reports show that IFN-a and IFN-
c may synergistically inhibit HCV replication in vitro [22,37,38]
and this effect is also reported for other viruses [39]. Nevertheless,
a study aimed to evaluate the antiviral impact of PhAg/IFN-a
combination is ongoing and may validate new combined
treatment strategies. Interestingly, PhAg-activated Vc9Vd2T -
cells are able not only to produce IFN-c but also to deploy many
Figure 4. IFN-a improves in vitro PhAg-induced IFN-c produc-
tion of Vc9Vd2 T-cells in HCV patients. (A,B) A quantitative
analysis of IFN-c production was performed in HD (n=35, Panel A) and
in HCV (n=24, Panel B) by ELISA after medium (white boxes), IFN-a
(grey boxes), PhAg (hatched boxes) and PhAg/IFN-a (dark grey boxes)
stimulation. Statistical analysis was performed by Mann-Whitney test,
**p,0.01 ***p,0.0001. (C) The percentage of increase in IFN-c
production after combined PhAg/IFN-a respect to single PhAg
stimulation was compared between HD (white bar) and HCV patients
(grey bar). Statistical analysis was performed by Mann-Whitney test,
**p,0.01.
doi:10.1371/journal.pone.0037014.g004
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neutrophils recruitment/activation [18], thus improving the
overall protective immune response capability. Noteworthy, IFN-
a effect on PhAg/response was found also in vivo in pre-clinical
trials on non-human primates, inducing an increase in IFN-c
amount in animals sera. A time-course study of in vivo IFN-a
treatment on Vc9Vd2 T-cell responsiveness to PhAg in HCV-
infected patients is currently in progress.
About possible mechanisms mediating this improvement, we
found that IFN-a acts by increasing IFN-c-mRNA persistence,
that may result in increased IFN-c translation levels. Similar ob-
servations were reported on NK cells, as IFN-c production after
IL-12 and IL-18 stimulation was regulated by mechanisms
involving IFN-c-mRNA stabilization [40]. Indeed, mRNA stabi-
lization is now considered as one of the main post-transcriptional
control mechanisms responsible for the initiation and resolution of
inflammation [41].
In recent years, a new attention on new direct antiviral drugs for
chronic HCV infection is growing. Nevertheless, a combination of
these new treatments with IFN-a/Ribavirin seem necessary to
avoid the emergence of drug resistance [6,42]. The definition of
other combined immunomodulating approaches may contribute
to optimize the antiviral response. In this context Vc9Vd2 T-cells
may represent a good target of immunomodulating strategies for
their ability to be easily activated in vivo by PhAgs [12,43–45]
without HLA restriction [46] and to orchestrate a complex net-
work of antiviral and immunomodulating activities [17–19]. We
show here for the first time that IFN-a, currently used in standard
therapy, is able to improve Vc9Vd2 T-cell responsiveness in HCV
patients. This, and the finding that IFN-c can act synergistically
with IFN-a to inhibit HCV replication [22,37,38], strengthen the
rational for testing combined standard antiviral and immunostim-
ulating therapeutical strategies. To this aim, future in vivo studies
on HCV-infected non-human primates aimed to define the anti-
viral capability of the combined treatment are necessary both to
assess safety and antiviral effectiveness of this combined approach,
and to disclose the cellular/molecular mechanisms involved.
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